Breaking News
Get 60% Off 0
Black Friday Sale! Save huge on InvestingPro
Get up to 60% off
Close

Nippon India Pharma Fund - Direct Plan - Bonus Plan (0P0000XVFI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
557.420 -3.340    -0.60%
27/11 - Closed. Currency in INR
Type:  Fund
Market:  India
Issuer:  Reliance Nippon Life Asset Management Ltd
ISIN:  INF204K01I27 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 86.89B
Reliance Pharma Fund - Direct Plan - Bonus Plan 557.420 -3.340 -0.60%

Nippon India Pharma Fund - Direct Plan - Bonus Plan Overview

 
Find basic information about the Nippon India Pharma Fund - Direct Plan - Bonus Plan mutual fund such as total assets, risk rating, Min. investment, market cap and category. Learn about the fund's agencies rating and risk rating, transparent information about the fund's management personal, policies of invested allocation and diversification, past performance. In addition we provide you related news, analysis tools, interactive charts and analysis articles. You may add 0P0000XVFI MF to your portfolio and watchlist to keep track with the fund's performance and users commentary. (ISIN: INF204K01I27)
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Rating
1-Year Change36.59%
Prev. Close560.763
Risk Rating
TTM Yield0%
ROE18.42%
IssuerReliance Nippon Life Asset Management Ltd
Turnover14%
ROA11.93%
Inception DateJan 01, 2013
Total Assets86.89B
Expenses0.91%
Min. Investment5,000
Market Cap714.74B
CategorySector - Healthcare
What is your sentiment on Reliance Pharma Fund - Direct Plan - Bonus Plan?
or
Market is currently closed. Voting is open during market hours.

Performance

Create Alert
Add to Watchlist
Add to/Remove from Watchlist  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

YTD 3M 1Y 3Y 5Y 10Y
Growth of 1000 1319 1054 1525 1768 3628 4621
Fund Return 31.89% 5.42% 52.48% 20.92% 29.4% 16.54%
Place in category 80 68 74 31 31 5
% in Category 96 61 96 38 55 18

Top Equity Funds by Nippon Life India Asset Management Ltd

  Name Rating Total Assets YTD% 3Y% 10Y%
  Reliance Small Cap Fund Bonus 622.6B 27.57 29.87 22.79
  Reliance Small Cap Fund Dividend 622.6B 26.66 31.00 23.10
  Reliance Small Cap Fund Growth 622.6B 27.57 29.87 22.79
  Reliance Small Cap Fund Dir Bon 622.6B 28.41 30.99 23.96
  Reliance Small Cap Fund Dir Gr 622.6B 27.71 32.10 24.28

Top Funds for Sector - Healthcare Category

  Name Rating Total Assets YTD% 3Y% 10Y%
  Reliance Pharma Fund - Bonus 86.89B 30.90 19.84 15.52
  Reliance Pharma Dividend Payout 86.89B 29.93 21.25 16.57
  Reliance Pharma Fund - Growth 86.89B 30.90 19.84 15.52
  Reliance Pharma Direct Growth 86.89B 31.89 20.92 16.54
  Reliance Pharma Dir Div Payout 86.89B 31.34 22.08 17.31

Top Holdings

Name ISIN Weight % Last Change %
  Sun Pharma INE044A01036 13.95 1,734.25 -0.87%
  Divi's Labs INE361B01024 9.16 5,951.80 -0.79%
  Lupin INE326A01037 8.06 1,998.40 -0.40%
  Cipla INE059A01026 5.54 1,492.75 +0.11%
  Apollo Hospitals INE437A01024 5.24 6,841.10 -2.03%

Technical Summary

Type Daily Weekly Monthly
Moving Averages Sell Buy Strong Buy
Technical Indicators Strong Sell Strong Sell Strong Buy
Summary Strong Sell Neutral Strong Buy
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0000XVFI Comments

Write your thoughts about Nippon India Pharma Fund - Direct Plan - Bonus Plan
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email